Graham Capital Management, L.P. Cyma Bay Therapeutics, Inc. Transaction History

Graham Capital Management, L.P.

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 14, 2023	SELL	$7.47 - $10.95 $570,670 - $836,525	-76,395 Reduced 52.7%	68,579 $750,000
Q1 2023 May 15, 2023	BUY	$5.88 - $9.59 $693,228 - $1.13 Million	117,896 Added 435.39%	144,974 $1.26 Million
Q4 2022 Feb 14, 2023	BUY	$3.22 - $6.27 $87,191 - $169,779	27,078 New	27,078 $169,000

1.88M

Ticker CBAY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,677,904
Description
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of pri...

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Graham Capital Management, L.P. with notifications on news.